See more : PT Semacom Integrated Tbk (SEMA.JK) Income Statement Analysis – Financial Results
Complete financial analysis of CorMedix Inc. (CRMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CorMedix Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sanofi (SNY) Income Statement Analysis – Financial Results
- Universal Cement Corporation (1104.TW) Income Statement Analysis – Financial Results
- The New York Times Company (NYT) Income Statement Analysis – Financial Results
- The Children’s Place, Inc. (PLCE) Income Statement Analysis – Financial Results
- Jiangsu Nata Opto-electronic Material Co., Ltd. (300346.SZ) Income Statement Analysis – Financial Results
CorMedix Inc. (CRMD)
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 65.41K | 190.94K | 239.23K | 283.27K | 429.80K | 329.33K | 224.11K | 210.13K | 189.27K | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 205.56K | 3.73K | 148.94K | 204.85K | 373.23K | 396.79K | 114.96K | 366.67K | 318.72K | 445.80K | 201.61K | 0.00 | 0.00 | 0.00 | 0.00 | 1.04M |
| Gross Profit | -205.56K | 61.67K | 42.00K | 34.39K | -89.97K | 33.01K | 214.36K | -142.57K | -108.59K | -256.53K | -199.60K | 0.00 | 0.00 | 0.00 | 0.00 | -1.04M |
| Gross Profit Ratio | 0.00% | 94.29% | 22.00% | 14.37% | -31.76% | 7.68% | 65.09% | -63.62% | -51.68% | -135.53% | -9,975.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.16M | 10.68M | 13.13M | 13.38M | 11.05M | 18.82M | 24.49M | 15.74M | 6.28M | 1.32M | 1.23M | 1.19M | 4.10M | 5.49M | 4.89M | 3.08M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.07M | 8.65M | 8.88M | 10.26M | 7.33M | 3.49M | 1.86M | 3.15M | 3.01M | 1.17M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 35.80M | 20.01M | 16.35M | 13.88M | 9.87M | 8.07M | 8.65M | 8.88M | 10.26M | 7.33M | 3.49M | 1.86M | 3.15M | 3.01M | 1.17M | 691.89K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.96M | 30.69M | 29.48M | 27.26M | 20.92M | 26.90M | 33.14M | 24.62M | 16.55M | 8.65M | 4.72M | 3.04M | 7.25M | 8.51M | 6.06M | 3.77M |
| Cost & Expenses | 48.96M | 30.69M | 29.48M | 27.46M | 21.29M | 27.29M | 33.25M | 24.99M | 16.86M | 9.09M | 4.92M | 3.04M | 7.25M | 8.51M | 6.06M | 4.82M |
| Interest Income | 0.00 | 326.02K | 14.40K | 116.07K | 322.67K | 36.62K | 110.71K | 126.77K | 60.39K | 2.71K | 668.00 | 1.97K | 12.04K | 23.44K | 2.13K | 25.90K |
| Interest Expense | 0.00 | 26.52K | 15.94K | 33.23K | 787.49K | 1.87K | 5.62K | 1.31K | 3.96K | 2.09K | 1.44M | 382.94K | 12.04K | 3.09M | 2.07M | 4.21M |
| Depreciation & Amortization | 70.76K | 209.04K | 177.02K | 143.49K | 73.29K | 74.22K | 36.89K | 25.60K | 15.08K | 15.07K | 5.16K | 7.02K | 12.25K | 12.17K | 9.95K | 1.04M |
| EBITDA | -48.89M | -30.05M | -29.38M | -27.02M | -20.63M | -26.75M | -32.97M | -24.62M | -18.17M | -20.44M | -7.68M | -3.04M | -7.19M | -8.47M | -6.04M | -3.75M |
| EBITDA Ratio | 0.00% | -46,321.48% | -15,421.12% | -11,329.92% | -7,302.40% | -6,241.92% | -9,963.77% | -10,980.81% | -7,889.64% | -4,693.90% | -245,581.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -48.96M | -30.62M | -29.44M | -27.22M | -21.01M | -26.86M | -32.92M | -24.76M | -16.65M | -8.90M | -4.92M | -3.04M | -7.25M | -8.51M | -6.06M | -4.82M |
| Operating Income Ratio | 0.00% | -46,819.91% | -15,417.51% | -11,378.44% | -7,416.31% | -6,250.44% | -9,997.39% | -11,048.80% | -7,925.56% | -4,703.30% | -245,646.93% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.62M | 336.65K | -22.83K | 23.67K | -485.98K | 34.57K | -85.80K | 117.29K | -1.53M | -11.55M | -4.22M | -380.97K | 41.86K | -2.68M | -2.07M | -4.18M |
| Income Before Tax | -46.34M | -30.29M | -29.46M | -27.20M | -21.49M | -26.83M | -33.01M | -24.64M | -18.19M | -20.45M | -9.13M | -3.43M | -7.21M | -11.19M | -8.12M | -9.00M |
| Income Before Tax Ratio | 0.00% | -46,305.23% | -15,429.47% | -11,368.54% | -7,587.87% | -6,242.40% | -10,023.45% | -10,996.46% | -8,655.37% | -10,806.25% | -456,426.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -585.62K | -1.25M | -5.17M | -5.06M | 36.44K | -31.27K | 1.31K | 3.96K | 2.09K | 1.44M | 1.97K | -493.86K | -280.92K | 2.13K | 0.00 |
| Net Income | -46.34M | -29.70M | -28.21M | -22.03M | -16.43M | -26.83M | -33.01M | -24.64M | -18.19M | -20.45M | -9.13M | -3.43M | -6.71M | -10.91M | -8.12M | -9.00M |
| Net Income Ratio | 0.00% | -45,409.90% | -14,774.70% | -9,207.70% | -5,801.29% | -6,242.40% | -10,023.45% | -10,996.46% | -8,655.37% | -10,806.25% | -456,426.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.91 | -0.74 | -0.75 | -0.77 | -0.68 | -1.51 | -2.99 | -3.25 | -2.90 | -4.77 | -3.30 | -1.50 | -2.94 | -5.76 | -47.40 | -3.94 |
| EPS Diluted | -0.91 | -0.74 | -0.75 | -0.77 | -0.68 | -1.51 | -2.99 | -3.25 | -2.90 | -4.77 | -3.30 | -1.50 | -2.94 | -5.76 | -47.40 | -3.94 |
| Weighted Avg Shares Out | 50.90M | 40.14M | 37.61M | 28.56M | 24.15M | 17.82M | 11.03M | 7.59M | 6.27M | 4.29M | 2.76M | 2.28M | 2.28M | 1.89M | 171.33K | 2.28M |
| Weighted Avg Shares Out (Dil) | 50.90M | 40.27M | 37.67M | 28.56M | 24.15M | 17.82M | 11.03M | 7.59M | 6.27M | 4.29M | 2.76M | 2.28M | 2.28M | 1.89M | 171.33K | 2.28M |
CorMedix Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12
BERKELEY HEIGHTS, N.J. , May 03, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report...
CorMedix Inc. Announces Scientific Advisory Board to Support Commercialization and Pipeline Development
BERKELEY HEIGHTS, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the formation of a new...
CorMedix Inc. to Present at the 21st Annual Needham Virtual Healthcare Conference
BERKELEY HEIGHTS, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that management will be presenting...
CorMedix Inc. (CRMD) CEO Matt David on Q4 2021 Results - Earnings Call Transcript
CorMedix Inc. (CRMD) CEO Matt David on Q4 2021 Results - Earnings Call Transcript
CorMedix (CRMD) Reports Q4 Loss, Tops Revenue Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of 9.09% and 40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CorMedix Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time
CorMedix (CRMD) Stock Jumps 14.8%: Will It Continue to Soar?
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update on March 29
BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its...
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CorMedix, Inc. (NASDAQ: CRMD) on behalf of long-term stockholders following a class action complaint that was filed against CorMedix on...
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CorMedix, Inc. (NASDAQ: CRMD) on behalf of long-term stockholders following a class action complaint that was filed against CorMedix on July...
Source: https://incomestatements.info
Category: Stock Reports